Filing Flows › Comparisons › CTOR vs VTGN
Citius Oncology vs Vistagen Therapeutics: CTOR and VTGN compared
Citius Oncology is the larger company: $1.5M of revenue in its latest quarter (Q3 FY26) against $1.5M for Vistagen Therapeutics (Q1 FY27). Citius Oncology is more profitable, with an operating margin of -583.5% against -904.3%.
Where the money goes: CTOR and VTGN
Citius Oncology (CTOR) · Q3 FY26
Citius Oncology, Q3 FY26: revenue $1.5M, operating margin -583.5%, net loss $8.9M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
Vistagen Therapeutics (VTGN) · Q1 FY27
Vistagen Therapeutics, Q1 FY27: revenue $1.5M (+505% year over year), operating margin -904.3%, net loss $13.0M, operating cash flow −$14.7M. The chart follows the revenue to costs, profit and cash.
| Citius Oncology (CTOR) | Vistagen Therapeutics (VTGN) | |
|---|---|---|
| Latest quarter | Q3 FY26 | Q1 FY27 |
| Revenue | $1.5M | $1.5M |
| Revenue growth, Y/Y | — | +505% |
| Operating margin | -583.5% | -904.3% |
| Net earnings | −$8.9M | −$13.0M |
| Net margin | -597.4% | -882.8% |
| Operating cash flow | −$2.7M | −$14.7M |
Questions
Which is bigger, Citius Oncology or Vistagen Therapeutics?
Citius Oncology is the larger company: $1.5M of revenue in its latest quarter (Q3 FY26) against $1.5M for Vistagen Therapeutics (Q1 FY27).
Is Citius Oncology or Vistagen Therapeutics growing faster?
Citius Oncology is more profitable, with an operating margin of -583.5% against -904.3%.
More: Citius Oncology earnings · how Citius Oncology makes money · Vistagen Therapeutics earnings · how Vistagen Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.